Psychedelics May Improve Mental Health by Targeting Inflammation, Study Suggests

• By Healing Maps Editorial Staff
• May 6, 2025June 26, 2026
• LSD articles Psilocybin Articles psilocybin mushrooms psychedelics
• With 0 comments

Last reviewed and updated: June 25, 2026.

Key Takeaways

A new study from the University of California, San Francisco provides a possible explanation for how psychedelics like LSD and psilocybin may ease symptoms of depression and anxiety. Researchers found that psychedelics may reduce inflammation in the brain and body by altering gene activity in immune cells. These findings open a window into how psychedelics might act as both neurological and immunological agents.

New: Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here

Looking for treatment? Find ketamine clinics closest to you as well as other psychedelic therapies in your area.

Investigating the Immune Connection

The study looked at two powerful psychedelics: lysergic acid diethylamide (LSD) and psilocybin, the active compound in magic mushrooms. Researchers exposed human immune cells to each compound in the lab. They then tracked changes in gene expression using single-cell RNA sequencing. This method allowed the team to measure how specific immune cells reacted at the genetic level.

What they found was striking. Both psychedelics changed the activity of hundreds of genes. Many of the affected genes were linked to inflammation, a known contributor to many mental health disorders. When the psychedelics reduced this activity, researchers began to understand a new mechanism that could be at play.

RELATED: Here’s Everything That Affects How Long Magic Mushrooms Last

Beyond the Brain

Much of the public discussion around psychedelics focuses on their effect on brain function. This study adds a new layer by showing that the body’s immune system also plays a role. The compounds did not just dampen inflammation directly. They reprogrammed how immune cells responded to stress and environmental signals.

While this was an in vitro study—meaning it took place outside the human body—the researchers believe their findings support the idea that psychedelics may help restore balance across brain and body systems. Future clinical studies will be needed to confirm these effects in patients.

A Promising Path Forward

Psychedelics remain controversial. But with this kind of cellular-level research, the scientific community continues to gain insight into their potential. These findings suggest that anti-inflammatory pathways may be just as important as the hallucinogenic experience in explaining why psychedelics are showing promise in mental health treatment.

The Psychedelic-Inflammation Connection: What the Research Means Clinically

The UCSF finding that psychedelics reduce inflammation-linked gene activity in immune cells represents one of several converging lines of evidence that depression and anxiety may have significant inflammatory components — and that psychedelics may work partly through anti-inflammatory pathways, not just through serotonin receptor activation or neural plasticity. Understanding this mechanism matters both for explaining why psychedelics work and for identifying which patients might benefit most.

The inflammatory basis of depression: growing evidence. Major depressive disorder in a substantial proportion of patients is now understood to involve chronic low-grade inflammation. Elevated levels of C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) are consistently found in patients with treatment-resistant depression — the same patients who tend to fail SSRIs and who respond best to ketamine and, in clinical trials, to psilocybin. This overlap is not a coincidence: antidepressants that work through serotonin pathways have limited efficacy in high-inflammation patients precisely because their depression may be driven more by inflammatory processes than by serotonin deficits. This is part of why drugs with novel mechanisms — ketamine, esketamine, and potentially psilocybin — can reach patients that SSRIs cannot.

What the UCSF study showed — and its limitations. The finding that LSD and psilocybin reduce inflammatory gene expression in peripheral blood mononuclear cells (PBMCs — immune cells) is mechanistically important but preliminary. The study examined gene expression in isolated cells, not in living patients. The jump from “reduces inflammatory genes in a cell” to “reduces clinical symptoms of depression through inflammation” is significant and not yet fully established. It does, however, provide a plausible mechanism for observations from clinical trials: psilocybin produces sustained remission in patients with treatment-resistant depression at rates far exceeding what inflammation-agnostic SSRIs achieve. If that effect is partially mediated by anti-inflammatory action, it could explain the durability differential.

Clinical implications: who might benefit most from psychedelic therapy based on inflammatory markers. If depression with elevated inflammatory markers is a distinct phenotype that responds better to drugs with anti-inflammatory mechanisms (ketamine, potentially psilocybin), then inflammatory biomarkers could eventually guide patient selection. Some researchers have proposed C-reactive protein (CRP) testing before prescribing antidepressants to identify patients likely to fail SSRIs and to route them earlier to ketamine or, once approved, psilocybin therapy. This remains speculative but represents an important direction for personalized psychiatry. Two Phase 3-ready psilocybin programs (Compass Pathways, Usona) could potentially include inflammatory subgroup analyses in their datasets.

Frequently Asked Questions

How might psychedelics reduce inflammation?

The UCSF study found that LSD and psilocybin alter gene expression in immune cells (peripheral blood mononuclear cells) — specifically reducing the activity of genes associated with inflammatory signaling. The proposed mechanisms include: (1) 5-HT2A receptor activity on immune cells — both LSD and psilocybin activate these receptors not just in neurons but in immune cells, potentially modulating cytokine production; (2) sigma-1 receptor activity — some psychedelic compounds activate sigma-1 receptors, which play a role in neuroinflammation regulation; (3) downstream BDNF effects — psilocybin and ketamine both stimulate BDNF (brain-derived neurotrophic factor), which has anti-neuroinflammatory properties. These mechanisms are not mutually exclusive and may work synergistically.

Is the inflammation-depression link established science?

The association between elevated inflammatory markers and depression is well-established — multiple large studies show significantly higher CRP, IL-6, and TNF-α in patients with major depressive disorder, particularly treatment-resistant cases. What is less established is the causal direction: does inflammation cause depression, does depression cause inflammation, or does a third factor (chronic stress, trauma, metabolic dysfunction) drive both? The answer appears to be “all three, depending on the patient” — which is why inflammatory-subtype depression is increasingly discussed as a distinct clinical phenotype rather than a universal feature of depression. Anti-inflammatory drugs alone (COX-2 inhibitors, TNF-alpha blockers) show modest antidepressant effects in trials of depressed patients with high inflammation, supporting the causal hypothesis.

Could psychedelics help with autoimmune or inflammatory conditions beyond depression?

This is an active area of research speculation, though clinical evidence is limited. If psychedelics genuinely modulate immune function and reduce inflammatory signaling, they could theoretically be relevant for conditions driven by chronic inflammation — including some autoimmune disorders, fibromyalgia, and inflammatory bowel disease. Early case reports and small observational studies have noted symptom improvement in some patients with inflammatory conditions following psychedelic use, but this is far from clinical-grade evidence. The challenge is that psychedelics are powerful drugs with significant psychological effects — delivering them for primarily anti-inflammatory purposes outside the context of supervised psychedelic sessions raises practical and regulatory challenges. The most likely near-term application is refining which depression patients to target, not extending into primary inflammatory indications.

How does ketamine’s anti-inflammatory effect compare to psilocybin’s?

Both ketamine and psilocybin have anti-inflammatory properties, but through different mechanisms. Ketamine (NMDA receptor antagonist) inhibits microglial activation and reduces pro-inflammatory cytokines through glutamate pathway modulation — it also has direct anti-inflammatory effects on peripheral immune cells. Psilocybin (5-HT2A agonist) appears to modulate immune gene expression and has downstream anti-neuroinflammatory effects through BDNF. Ketamine’s anti-inflammatory effects are more immediately apparent (consistent with its rapid-onset antidepressant action); psilocybin’s may contribute to its durability — the “single-session, lasting effects” characteristic that differentiates it from ketamine’s need for maintenance dosing. Spravato (esketamine) is currently the only FDA-approved agent in this category, making it the most accessible option for patients with inflammatory-subtype treatment-resistant depression.

RELATED READING

• The Countdown to Approval: Psychedelic Clinical Trials
• Johnson & Johnson’s Spravato Surges Toward Blockbuster Status
• 5-MeO-DMT With SSRIs: Positive Data Shows Promise